Author

Lei Wang

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Attenuated Salmonella-Mediated Delivery of GSDMD Potentiates PD-1 Blockade Therapy against Melanoma

Immunotherapy has emerged as a core therapeutic strategy for melanoma. Programmed death protein 1 (PD-1) is a critical immune checkpoint molecule that restrains host anti-tumor immunity, and therapeutic agents blocking the PD-1 signaling pathway have been widely deployed in clinical practice. Nevertheless, single-agent...

Xiao-Long Jia, Ying-Jie Yuan, Yu-Jing Huang et al. · bioRxiv · 0 citations

Open access Sep 2026

Single-cell and bulk transcriptomic analyses define an IFI27-centered interferon-response epithelial state in bladder cancer and its transcriptional response to irradiation

Background Interferon-responsive tumor-cell states can simultaneously increase immune visibility and induce immune-regulatory programs, yet their epithelial-cell distribution and treatment responsiveness in bladder cancer remain incompletely defined. We sought to resolve a reproducible epithelial interferon-response st...

Yan-Ru Ji, Yang-Yang Zhang, Xiao-Dong Liu et al. · Frontiers in Cell and Develo... · 0 citations

Open access Aug 2026

Combination therapy with Nifuroxazide and Lenvatinib exerts superior anti-hepatocellular carcinoma effect by enhancing the anti-tumor immune response

Background Lenvatinib is a first-line multi-target tyrosine kinase inhibitor for hepatocellular carcinoma (HCC) that exerts anti-angiogenic effects by blocking VEGF signaling. However, its clinical efficacy is often compromised by adaptive resistance. Nifuroxazide, an anti-diarrheal agent, has been identified by our gr...

Jing Yang, Jia-Xin Geng, Yue-Ling Yin et al. · Frontiers in Oncology · 0 citations